Collagen synthesis and deposition

Collagen synthesis and deposition is a complex, multi-step biological process essential for maintaining the structural integrity of the extracellular matrix (ECM) in connective tissues [NIH, 2016]. It involves the intracellular transcription and translation of procollagen chains, post-translational modifications such as prolyl and lysyl hydroxylation, and the extracellular assembly of collagen fibrils stabilized by cross-linking enzymes like lysyl oxidase (LOX) [NIH, 2024; NIH, 2011]. While critical for normal wound healing and tissue repair, dysregulation of this process leads to pathological conditions, most notably fibrosis, where excessive collagen accumulation impairs organ function [Frontiers, 2024; MDPI, 2023]. In the tumor microenvironment, increased collagen deposition (desmoplasia) creates a physical barrier that promotes tumor progression, metastasis, and limits the delivery of therapeutic agents [NIH, 2024; Preprints, 2024]. Therapeutic strategies targeting this process include inhibiting pro-fibrotic signaling pathways (e.g., TGF-beta), blocking cross-linking enzymes, or promoting collagen degradation to restore tissue homeostasis [NIH, 2023; NIH, 2025]. Monitoring this process often involves measuring circulating neoepitopes of collagen synthesis and degradation, such as PRO-C3 and P1NP, which serve as biomarkers for disease progression and treatment efficacy [Nordic Bioscience, 2019; NIH, 2018].

Other names

Collagen productionCollagen fibrillogenesisFibrogenesisExtracellular matrix depositionCollagen remodeling

Drugs targeting this process act by inhibiting pro-fibrotic signaling (e.g., TGF-beta/Smad pathway), blocking post-translational modification enzymes (e.g., prolyl hydroxylase, lysyl oxidase), inhibiting collagen gene transcription, or directly degrading extracellular collagen fibers using collagenases [Frontiers, 2024; NIH, 2011; MDPI, 2023].